微信公众号

官网二维码

中国癌症防治杂志 ›› 2025, Vol. 17 ›› Issue (3): 297-304.doi: 10.3969/j.issn.1674-5671.2025.03.06

• 肝脏肿瘤专栏 • 上一篇    下一篇

GCLC启动子甲基化在微囊藻毒素-LR诱导肝细胞恶性转化中的作用及5⁃氮杂-2'-脱氧胞苷的干预影响

  

  1. 广西医科大学公共卫生学院环境卫生学教研室,广西高校高发疾病预防与控制研究重点实验室
  • 出版日期:2025-06-25 发布日期:2025-07-10
  • 通讯作者: 农清清 E-mail:nnqq26@163.com
  • 基金资助:
    国家自然科学基金项目(81960582;82360635)

Role of GCLC promoter methylation on microcystin?LR?induced hepatocyte malignant transformation and the interventional effects of 5?aza?2′?deoxycytidine

  • Online:2025-06-25 Published:2025-07-10

摘要: 目的 探讨谷氨酰半胱氨酸连接酶催化亚基(glutamate⁃cysteine ligase catalytic subunit,GCLC)启动子甲基化在微囊藻毒素⁃LR(microcystin⁃LR,MCLR)诱导肝细胞恶性转化中的作用,并评估DNA甲基化抑制剂5⁃氮杂⁃2'⁃脱氧胞苷(5⁃aza⁃2'⁃deoxycytidine,5⁃aza)进行干预的效果。方法 将WRL68细胞长期暴露于10 nmol/L MCLR,培养至第25代,建立细胞恶性转化模型。实验分为4组:对照组、MCLR染毒组、5⁃aza处理组和MCLR+5⁃aza干预组。使用Agena MassArray核酸质谱技术评估GCLC启动子甲基化状态;Western blot检测GCLC、DNA甲基转移酶(DNA methyltransferases,DNMTs)蛋白水平;分别通过集落形成、软琼脂克隆和Transwell实验检测细胞增殖、侵袭和迁移能力。此外,采用相应试剂盒检测细胞的谷氨酰半胱氨酸连接酶(glutamate⁃cysteine ligase,GCL)活性、谷胱甘肽(glutathione,GSH)含量及8⁃羟基脱氧鸟苷(8⁃hydroxy⁃2'⁃deoxyguanosine,8⁃OHdG‌‌)水平。结果 在MCLR诱导WRL68细胞恶性转化过程中,GCLC的启动子甲基化水平逐渐升高,同时GCLC mRNA和蛋白表达水平逐渐下降(均P<0.05)。第25代MCLR染毒组DNMT⁃1、DNMT⁃3a、DNMT⁃3b蛋白均呈高表达,而GCL活性、GSH含量明显下降,8⁃OHdG水平明显升高(均P<0.05)。5⁃aza干预可降低第25代MCLR染毒组GCLC启动子甲基化水平,明显上调GCLC的mRNA和蛋白表达,增加GCL活性和GSH含量,降低8⁃OHdG‌‌水平(均P<0.05)。此外,5⁃aza干预还可减弱MCLR染毒组细胞迁移、侵袭、细胞集落形成能力(均P<0.05)。结论 GCLC启动子甲基化促进MCLR诱导的WRL68细胞恶性转化。5⁃aza可能通过下调DNMTs的表达,抑制GCLC启动子的高甲基化,重新激活沉默的GCLC基因表达,恢复其肿瘤抑制功能,从而抑制恶性转化。

关键词: 谷氨酰半胱氨酸连接酶催化亚基, DNA甲基化, 5?氮杂?2'?脱氧胞苷, 微囊藻毒素?LR, 肝细胞恶性转化

Abstract: Objective To investigate the role of glutamate⁃cysteine ligase catalytic subunit (GCLC) promoter methylation in the malignant transformation of hepatocyte induced by microcystin⁃LR (MCLR), as well as to assess the intervention effects of the DNA methylation inhibitor 5⁃aza⁃2'⁃deoxycytidine (5⁃aza). Methods A malignant transformation model was established by subjecting WRL68 cells to chronic exposure to 10 nmol/L MCLR until passage 25. Four experimental groups were constituted: the control group, the MCLR⁃exposed group, the 5⁃aza intervention group, and the MCLR plus 5⁃aza intervention group. The methylation status of the  GCLC gene promoter was assessed using Agena MassArray mass spectrometry⁃based nucleic acid analysis technology. Protein expression levels of GCLC and DNA methyltransferases (DNMTs) were determined via Western blot. Cellular proliferation, invasion, and migration capabilities were detected via Colony formation assay, soft agar assay, and Transwell assays, respectively. Additionally, glutamate⁃cysteine ligase (GCL) activity, glutathione (GSH) content, and 8⁃hydroxydeoxyguanosine (8⁃OHdG) levels were quantified using corresponding reagent kits. Results During the MCLR⁃induced malignant transformation of WRL68 cells, there was a progressive increase in the methylation level of the GCLC promoter, accompanied by a gradual decrease in both mRNA and protein expression levels (all  P<0.05). At passage 25 in the MCLR⁃exposed group, there was a significant elevation in the protein levels of DNMT⁃1, DNMT⁃3a, and DNMT⁃3b, while GCL activity and GSH content were markedly reduced, and 8⁃OHdG levels were significantly elevated (all P<0.05). Intervention with 5⁃aza at passage 25 in the MCLR⁃exposed group resulted in a reduction of GCLC promoter methylation levels, significantly upregulating GCLC mRNA and protein expression, enhanced GCL activity and GSH content, and reduced 8⁃OHdG levels (all P<0.05). Furthermore, 5⁃aza attenuated the migration, invasion, and cell colony formation capabilities of the MCLR⁃exposed group (all P<0.05). Conclusions GCLC promoter methylation contributes to the MCLR⁃induced malignant transformation of WRL68 cells. 5⁃aza may inhibit this malignant transformation by downregulating DNMTs expression, suppressing hypermethylation of the GCLC promoter, reactivating the expression of the silenced GCLC gene, and restoring its tumor⁃suppressive function.

Key words: Glutamate?cysteine ligase catalytic subunit, DNA methylation, 5?aza?2'?deoxycytidine, Microcystin?LR, Hepatocyte  malignant transformation

中图分类号: 

  • R730.2